KB801
AXP000197.1 · Viral vector gene therapy
- Platform
- HSV-1 (replication-defective)
- Targets
- NGF
- Originator
- Krystal Biotech
- Sponsor
- Krystal Biotech
Names
Virus
- Role
- In vivo gene transfer
- Family
- Herpesviridae
- Virus
- herpes simplex virus 1 (NCBI Taxonomy 10298)
- Replication
- non replicating
- Modifications
- replication-defective HSV-1 backbone; NGF cassette
- Transgenes
- NGF
- Route
- topical
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06999733 | A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis | Recruiting | Phase 1/2 | 2025-07-07 | 2026-12 | 60 | Neurotrophic Keratitis |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39798579 | Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. | Lancet (London, England) | 2025 | name in title: EMERALD-1 |
Other papers
Preclinical studies, reviews and other papers that name it.
No confirmed other papers yet.
Unconfirmed matches (3)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41503570 | Impact of LEAP-012 and EMERALD-1 in the management of HCC. | JHEP reports : innovation in hepatology | 2026 | name in title: EMERALD-1 |
| PMID 41046144 | Unexplained early deaths in EMERALD-1: is liver failure the reason? | Lancet (London, England) | 2025 | name in title: EMERALD-1 |
| PMID 41046145 | Unexplained early deaths in EMERALD-1: is liver failure the reason? - Authors' reply. | Lancet (London, England) | 2025 | name in title: EMERALD-1 |
Notes
Redosable eye-drop HSV-1 gene therapy driving corneal/ocular surface expression of nerve growth factor (NGF) in neurotrophic keratitis; phase 1/2 EMERALD-1, NCT06999733, dosed twice weekly for 8 weeks. The press release does not name the vector explicitly; HSV-1 is Krystal's platform.
How to cite
KB801 (AXP000197.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000197.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.